dc.contributor.author |
Marrodán, Mariano |
|
dc.contributor.author |
Crema, Santiago |
|
dc.contributor.author |
Rubstein, Adrián |
|
dc.contributor.author |
Alessandro, Lucas |
|
dc.contributor.author |
Fernández, José |
|
dc.contributor.author |
Correale, Jorge |
|
dc.contributor.author |
Ysrraelit, María Célica |
|
dc.date.accessioned |
2021-08-24T17:48:41Z |
|
dc.date.available |
2021-08-24T17:48:41Z |
|
dc.date.issued |
2021-07-25 |
|
dc.identifier.citation |
39. Marrodan M, Crema S, Rubstein A, Alessandro L, Fernandez J, Correale J, Ysrraelit MC. Therapeutic plasma exchange in MS refractory relapses: Long-term outcome. Mult Scler Relat Disord. 2021 Jul 25;55:103168. doi: 10.1016/j.msard.2021.103168 |
es_ES |
dc.identifier.uri |
https://doi.org/10.1016/j.msard.2021.103168 |
|
dc.identifier.uri |
https://repositorio.fleni.org.ar/xmlui/handle/123456789/561 |
|
dc.description.abstract |
Introduction
Therapeutic plasma exchange (TPE) is considered a treatment option for steroid-refractory multiple sclerosis (MS) relapses. Our objective was to assess long-term clinical response to TPE in MS steroid-refractory exacerbations.
Methods
Retrospective study of relapsing remitting MS (RRMS) patients presenting intravenous methylprednisolone (IVMPS)-refractory relapses, who underwent TPE. Response to TPE was assessed at 1, 3, 6, 12 and 24-months post-treatment, and compared to a second group of RRMS patients with similar demographic and clinical characteristics presenting, IVMPS-refractory relapses but not treated with TPE. Multivariate regression analysis was used to assess potential predictors of significant clinical response.
Results
Between 2011 to 2020, a total of 23 RRMS patients were treated with TPE. Twenty-one patients not receiving the treatment served as controls. No differences in demographic or clinical characteristics, or predictors of clinical improvement after TPE were detected between groups. Seventy-eight percent of patients treated with TPE presented clinical improvement at 24 months. TPE-treated patients presented lower EDSS scores at 6 and at 24 months. Younger age, presence of gadolinium-enhancing lesions and TPE treatment were associated with better clinical outcomes. No life-threatening side effects were reported.
Conclusions
TPE is a safe and well tolerated procedure that decreases long-term disability in RRMS patients with IVMPS-refractory relapses. |
es_ES |
dc.language.iso |
eng |
es_ES |
dc.publisher |
Elsevier |
es_ES |
dc.rights |
info:eu-repo/semantics/openAccess |
|
dc.rights.uri |
https://creativecommons.org/licenses/by/2.5/ar/ |
|
dc.subject |
Multiple Sclerosis, Relapsing-Remitting |
es_ES |
dc.subject |
Esclerosis Múltiple Recurrente-Remitente |
es_ES |
dc.subject |
Plasma Exchange |
es_ES |
dc.subject |
Intercambio Plasmático |
es_ES |
dc.title |
Therapeutic plasma exchange in MS refractory relapses: Long-term outcome |
es_ES |
dc.type |
info:eu-repo/semantics/article |
es_ES |
dc.type |
info:eu-repo/semantics/publishedVersion |
|
dc.description.fil |
Fil: Marrodán, Mariano. Fleni. Departamento de Neurología; Argentina. |
|
dc.description.fil |
Fil: Crema, Santiago. Fleni. Departamento de Neurología; Argentina |
|
dc.description.fil |
Fil: Rubstein, A. Merck KGaA; Alemania. |
|
dc.description.fil |
Fil: Alessandro, Lucas. Fleni. Departamento de Neurología; Argentina. |
|
dc.description.fil |
Fil: Fernández, José. Fleni. Departamento de Medicina Interna. Hematología y Trombosis; Argentina. |
|
dc.description.fil |
Fil: Correale, Jorge. Fleni. Departamento de Neurología. Servicio de Neuroinmunología y Enfermedades Desmielinizantes; Argentina |
|
dc.description.fil |
Fil: Ysrraelit, Maria Célica. Fleni. Departamento de Neurología; Argentina. |
|
dc.relation.ispartofCOUNTRY |
Países Bajos |
|
dc.relation.ispartofCITY |
Amsterdam |
|
dc.relation.ispartofTITLE |
Multiple sclerosis and related disorders |
|
dc.relation.ispartofISSN |
2211-0356 |
|
dc.type.snrd |
info:ar-repo/semantics/artículo |
es_ES |